Literature DB >> 25727557

Landscape of neoadjuvant therapy for breast cancer.

Tufia C Haddad1, Matthew P Goetz.   

Abstract

Neoadjuvant chemotherapy provides clinical outcomes equivalent to those achieved when the same regimen is provided in the adjuvant setting. The therapeutic response to neoadjuvant treatment may include a reduction in tumor burden that alleviates the morbidity associated with locoregional therapy. Important prognostic information can be gained based on the response to treatment and knowing the quantity and biology of the residual disease. The evaluation of investigational agents in the neoadjuvant setting is of particular value for accelerating drug development. This review highlights landmark trials and contemporary perspectives on neoadjuvant chemotherapy and hormonal therapy, treatment response as a prognostic biomarker, use of the neoadjuvant paradigm for new drug development, and clinical advances in neoadjuvant therapy by molecular subtype of breast cancer.

Entities:  

Mesh：

Year:  2015        PMID： 25727557      PMCID： PMC4484769          DOI： 10.1245/s10434-015-4405-7

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   5.344


  53 in total

1.  Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.

Authors:  Luca Gianni; Wolfgang Eiermann; Vladimir Semiglazov; Ana Lluch; Sergei Tjulandin; Milvia Zambetti; Angela Moliterni; Federico Vazquez; Mikhail J Byakhov; Mikhail Lichinitser; Miguel Angel Climent; Eva Ciruelos; Belen Ojeda; Mauro Mansutti; Alla Bozhok; Domenico Magazzù; Dominik Heinzmann; Jutta Steinseifer; Pinuccia Valagussa; Jose Baselga
Journal:  Lancet Oncol       Date:  2014-03-20       Impact factor: 41.316

2.  Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

Authors:  Edith A Perez; Edward H Romond; Vera J Suman; Jong-Hyeon Jeong; Nancy E Davidson; Charles E Geyer; Silvana Martino; Eleftherios P Mamounas; Peter A Kaufman; Norman Wolmark
Journal:  J Clin Oncol       Date:  2011-07-18       Impact factor: 44.544

3.  Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

Authors:  Gunter von Minckwitz; Andreas Schneeweiss; Sibylle Loibl; Christoph Salat; Carsten Denkert; Mahdi Rezai; Jens U Blohmer; Christian Jackisch; Stefan Paepke; Bernd Gerber; Dirk M Zahm; Sherko Kümmel; Holger Eidtmann; Peter Klare; Jens Huober; Serban Costa; Hans Tesch; Claus Hanusch; Jörn Hilfrich; Fariba Khandan; Peter A Fasching; Bruno V Sinn; Knut Engels; Keyur Mehta; Valentina Nekljudova; Michael Untch
Journal:  Lancet Oncol       Date:  2014-04-30       Impact factor: 41.316

4.  Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.

Authors:  Matthew J Ellis; Vera J Suman; Jeremy Hoog; Li Lin; Jacqueline Snider; Aleix Prat; Joel S Parker; Jingqin Luo; Katherine DeSchryver; D Craig Allred; Laura J Esserman; Gary W Unzeitig; Julie Margenthaler; Gildy V Babiera; P Kelly Marcom; Joseph M Guenther; Mark A Watson; Marilyn Leitch; Kelly Hunt; John A Olson
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

5.  18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.

Authors:  Geraldine Gebhart; Cristina Gámez; Eileen Holmes; Javier Robles; Camilo Garcia; Montserrat Cortés; Evandro de Azambuja; Karine Fauria; Veerle Van Dooren; Gursel Aktan; Maria Antonia Coccia-Portugal; Sung-Bae Kim; Peter Vuylsteke; Hervé Cure; Holger Eidtmann; José Baselga; Martine Piccart; Patrick Flamen; Serena Di Cosimo
Journal:  J Nucl Med       Date:  2013-10-03       Impact factor: 10.057

6.  Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial.

Authors:  Aman U Buzdar; Vera J Suman; Funda Meric-Bernstam; A Marilyn Leitch; Matthew J Ellis; Judy C Boughey; Gary Unzeitig; Melanie Royce; Linda M McCall; Michael S Ewer; Kelly K Hunt
Journal:  Lancet Oncol       Date:  2013-11-13       Impact factor: 41.316

7.  Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).

Authors:  A Schneeweiss; S Chia; T Hickish; V Harvey; A Eniu; R Hegg; C Tausch; J H Seo; Y-F Tsai; J Ratnayake; V McNally; G Ross; J Cortés
Journal:  Ann Oncol       Date:  2013-05-22       Impact factor: 32.976

8.  Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.

Authors:  David Cameron; Julia Brown; Rebecca Dent; Christian Jackisch; John Mackey; Xavier Pivot; Guenther G Steger; Thomas M Suter; Masakazu Toi; Mahesh Parmar; Rita Laeufle; Young-Hyuck Im; Gilles Romieu; Vernon Harvey; Oleg Lipatov; Tadeusz Pienkowski; Paul Cottu; Arlene Chan; Seock-Ah Im; Peter S Hall; Lida Bubuteishvili-Pacaud; Volkmar Henschel; Regula J Deurloo; Celine Pallaud; Richard Bell
Journal:  Lancet Oncol       Date:  2013-08-07       Impact factor: 41.316

9.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.

Authors:  C Davies; J Godwin; R Gray; M Clarke; D Cutter; S Darby; P McGale; H C Pan; C Taylor; Y C Wang; M Dowsett; J Ingle; R Peto
Journal:  Lancet       Date:  2011-07-28       Impact factor: 79.321

Review 10.  Functional magnetic resonance: biomarkers of response in breast cancer.

Authors:  Elizabeth A M O'Flynn; Nandita M DeSouza
Journal:  Breast Cancer Res       Date:  2011-02-23       Impact factor: 6.466
View more
  15 in total

1.  Expression of NF-κB-inducing kinase in breast carcinoma tissue and its clinical significance.

Authors:  Xuliang Zhang; Yong Wang; Zheyu Mao; Danqing Huang; Junwei Zhou; Xudong Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

2.  RAS pathway biomarkers for breast cancer prognosis.

Authors:  Lauren L Siewertsz van Reesema; Michael P Lee; Vasilena Zheleva; Janet S Winston; Caroline F O'Connor; Roger R Perry; Richard A Hoefer; Amy H Tang
Journal:  Clin Lab Int       Date:  2016-11

3.  Analysis of Circulating Tumor DNA to Predict Neoadjuvant Therapy Effectiveness and Breast Cancer Recurrence.

Authors:  Shuai Hao; Wuguo Tian; Jianjie Zhao; Yi Chen; Xiaohua Zhang; Bo Gao; Yujun He; Donglin Luo
Journal:  J Breast Cancer       Date:  2020-07-10       Impact factor: 3.588

4.  Epithelial-mesenchymal transition sensitizes breast cancer cells to cell death via the fungus-derived sesterterpenoid ophiobolin A.

Authors:  Keighley N Reisenauer; Yongfeng Tao; Provas Das; Shuxuan Song; Haleigh Svatek; Saawan D Patel; Sheridan Mikhail; Alec Ingros; Peter Sheesley; Marco Masi; Angela Boari; Antonio Evidente; Alexander Kornienko; Daniel Romo; Joseph Taube
Journal:  Sci Rep       Date:  2021-05-20       Impact factor: 4.379

5.  P-glycoprotein-mediated chemoresistance is reversed by carbonic anhydrase XII inhibitors.

Authors:  Joanna Kopecka; Gregory M Rankin; Iris C Salaroglio; Sally-Ann Poulsen; Chiara Riganti
Journal:  Oncotarget       Date:  2016-12-27

6.  A combination of Nottingham prognostic index and IHC4 score predicts pathological complete response of neoadjuvant chemotherapy in estrogen receptor positive breast cancer.

Authors:  Weige Tan; Wei Luo; Weijuan Jia; Gehao Liang; Xinhua Xie; Wenbo Zheng; Erwei Song; Fengxi Su; Chang Gong
Journal:  Oncotarget       Date:  2016-12-27

7.  Circulating tumor DNA dynamics using patient-customized assays are associated with outcome in neoadjuvantly treated breast cancer.

Authors:  Timothy M Butler; Christopher T Boniface; Katie Johnson-Camacho; Shaadi Tabatabaei; Daira Melendez; Taylor Kelley; Joe Gray; Christopher L Corless; Paul T Spellman
Journal:  Cold Spring Harb Mol Case Stud       Date:  2019-04-01

8.  Neoadjuvant Chemotherapy Exerts Selection Pressure Towards Luminal Phenotype Breast Cancer.

Authors:  Giulia Galli; Giacomo Bregni; Stefano Cavalieri; Luca Porcu; Paolo Baili; Amash Hade; Francesca Di Salvo; Milena Sant; Roberto Agresti; Massimiliano Gennaro; Secondo Folli; Maria C De Santis; Biagio Paolini; Maria L Carcangiu; Filippo de Braud; Serena Di Cosimo
Journal:  Breast Care (Basel)       Date:  2017-12-12       Impact factor: 2.860

9.  SIAH and EGFR, Two RAS Pathway Biomarkers, are Highly Prognostic in Locally Advanced and Metastatic Breast Cancer.

Authors:  Lauren L Siewertsz van Reesema; Vasilena Zheleva; Janet S Winston; Rick J Jansen; Carolyn F O'Connor; Andrew J Isbell; Minglei Bian; Rui Qin; Patricia T Bassett; Virginia J Hinson; Kimberly A Dorsch; Brad W Kirby; Robert E Van Sciver; Angela M Tang-Tan; Elizabeth A Harden; David Z Chang; Cynthia A Allen; Roger R Perry; Richard A Hoefer; Amy H Tang
Journal:  EBioMedicine       Date:  2016-08-14       Impact factor: 8.143

10.  Reduced symptom burden with the support of an interactive app during neoadjuvant chemotherapy for breast cancer - A randomized controlled trial.

Authors:  Maria Fjell; Ann Langius-Eklöf; Marie Nilsson; Yvonne Wengström; Kay Sundberg
Journal:  Breast       Date:  2020-03-20       Impact factor: 4.380
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.